CYCLERION THERAPEUTICS INC (CYCN)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.25-14.31%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CYCN
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||
| Revenues | — | 2.1 | 2.0 | 0.0 | 0.3 | 3.9 | 2.3 | 4.5 |
| Total Revenues | — | 2.1 | 2.0 | 0.0 | 0.3 | 3.9 | 2.3 | — |
| Operating Expenses & Income | ||||||||
| R&D Expenses | — | 1.0 | 0.3 | 1.5 | 6.0 | 37.6 | 56.4 | 95.1 |
| Operating Income | (6.8) | (5.0) | (3.6) | (13.0) | (18.5) | (55.2) | (81.3) | (125.0) |
| Earnings from Continuing Operations | ||||||||
| Interest & Investment Income | — | — | — | — | — | — | 0.6 | 2.0 |
| Other Non-Operating Income / Expenses | 0.1 | 1.4 | 0.6 | 0.4 | 0.3 | (0.0) | 0.6 | — |
| Asset Writedown | — | — | — | 3.3 | 0.0 | — | — | — |
| EBT, Incl. Unusual Items | — | (3.5) | (3.1) | (5.3) | (44.1) | (51.6) | (122.4) | (122.4) |
| Income Tax Expense | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Earnings from Continuing Operations | — | — | (3.1) | (12.6) | (18.2) | — | — | — |
| Net Income | ||||||||
| Net Income | (6.7) | (3.5) | (3.1) | (5.3) | (44.1) | (51.6) | (77.8) | (123.0) |
| Per Share | ||||||||
| Basic EPS | (1.58) | (1.11) | (1.21) | (2.25) | (20.28) | (1.32) | — | — |
| Diluted EPS | (1.58) | (1.11) | (1.21) | (2.25) | (20.28) | (1.32) | — | — |
| Basic Weighted Avg Shares | 4.3 | 3.2 | 2.5 | 2.3 | 2.2 | 39.1 | — | — |
| Diluted Weighted Avg Shares | 4.3 | 3.2 | 2.5 | 2.3 | 2.2 | 39.1 | — | — |
| Supplemental | ||||||||
| EBITDA | — | — | — | (13.0) | (18.5) | (54.7) | (79.0) | (122.3) |
| EBIT | (6.8) | (5.0) | (3.6) | (13.0) | (18.5) | (55.2) | (81.3) | (125.0) |
| Effective Tax Rate | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.